|
KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. |
| |
|
Honoraria - Bristol-Myers Squibb; Guardant Health; Innovent Biologics; Merck KGaA; Roche; SERVIER |
Consulting or Advisory Role - Roche |
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck KGaA (Inst); MSD (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Innovent Biologics; Merck KGaA; MSD; Roche; SERVIER |
| |
|
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER; Ventana Medical Systems |
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Clovis Oncology; GamaMabs Pharma; Gastrointestinal Cancers Advice; HalioDX; MSD Oncology; Pierre Fabre; SERVIER; Tesaro |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche/Genentech; Ventana Medical Systems |
| |
|
Employment - Asan Medical Center |
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Sanofi (Inst) |
| |
|
Research Funding - Merck Sharp & Dohme |
| |
|
Research Funding - 2cureX (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MSD (Inst) |
| |
|
Consulting or Advisory Role - Bayer (Inst); Nordic Bioscience (Inst) |
Travel, Accommodations, Expenses - Nordic Bioscience |
| |
|
Honoraria - 3A Pharmaceuticals & Diagnostics; Ipsen; Novartis; SERVIER |
Consulting or Advisory Role - Ipsen |
Travel, Accommodations, Expenses - Amgen; Roche |
| |
|
Honoraria - Advanced Accelerator Applications; Advanz Pharma; AstraZeneca (I); Bayer; Boehringer Ingelheim (I); Bristol-Myers Squibb (I); Gilead Sciences (I); HMP; Ipsen; Lilly (I); MERCK; Merck (I); Midatech Pharma; MSD; NOVARTIS; PFIZER; PharmaMar; PharmaMar (I); Pierre Fabre; ROCHE; Roche (I); Sanofi; SERVIER; SERVIER (I); Sysmex (I) |
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; HMP; Ipsen; Merck; MSD; Novartis; Pfizer; PharmaMar; Pierre Fabre |
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Merck; Roche |
| |
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Sanofi |
Research Funding - Amgen (Inst); MSD (Inst); Novocure (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck; Roche; Sanofi |
| |
|
Honoraria - Amgen; Merck; MSD Oncology; Roche; Sanofi/Aventis; SERVIER |
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst); Ventana Medical Systems (Inst) |
Travel, Accommodations, Expenses - Servier |
| |
Christelle De La Fouchardiere |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Pierre Fabre; Roche; SERVIER; Shire |
|
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; Roche; SERVIER |
| |
|
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; SERVIER |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst) |
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Hutchison MediPharma (Inst); IGM (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novocure (Inst); Numab (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Treadwell Therapeutics (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical |
| |
|
Honoraria - Merck Sharp & Dohme |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst) |
| |
|
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
| |
Mohammed Zulfiqar Husain Farooqui |
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
| |
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
| |
|
Leadership - Jounce Therapeutics; Personal Genome Diagnostics |
Stock and Other Ownership Interests - Amgen (I); Four Paws; Jounce Therapeutics; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Thrive Earlier Detection Corp; Zydecom |
Consulting or Advisory Role - Four Paws; Innovatus Capital Partners; Merck; Neophore; Personal Genome Diagnostics; Zydecom |
Research Funding - Merck (Inst) |
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses |
Travel, Accommodations, Expenses - Merck |